Skip to main content

Distinguished Speaker Series | Celso Henrique Freitas Alves, PhD

-
Location
https://ucihealth.zoom.us/j/92801383742?pwd=vfI4WBKGwibdfbtyznYWvAbSg3CccO.1
Event Type

Add to Calendar: Outlook | Google | iCal

The Center for Translational Vision Research Distinguished Speaker Series, also known as "Friday Seminars" showcases innovative research across the world. The seminar series has now been expanded to include lectures by experts on topics ranging from Ophthalmology, Genetics, Biochemistry, Neurobiology, Imaging, Computational Sciences to Novel Ophthalmic Treatments.

All talks are hybrid. You can join us in person at

The Falling Leaves Foundation Building, Main Entrance Level

Conference Room (2nd Floor by signage)

847 Health Sciences Quad

You can also join us by zoom. Zoom link and information are on your right and in the calendar links above.

May 8, 2026 | Celso Henrique Freitas Alves, PhD

CRB1 and EYS: From Human Cohorts and Disease Models to Gene Therapy

 

Learn More About the Distinguished Speaker Series

Featured


Celso Henrique Freitas Alves, PhD
Celso Henrique Freitas Alves, PhD
  • Celso Henrique Freitas Alves, PhD, Assistant Researcher, Vision Sciences/Gene Editing, Centro de Inovação em Biomedicina e Biotecnologia (CiBB), University of Coimbra

Celso Henrique Freitas Alves, PhD, is an Assistant Researcher in Vision Sciences and Gene Editing at the Centro de Inovação em Biomedicina e Biotecnologia (CiBB) at the University of Coimbra in Portugal. His research focuses on the molecular mechanisms underlying inherited retinal diseases and the development of gene-based therapeutic strategies to treat these disorders. Dr. Alves’s work centers on the CRB1 gene and its role in retinal development and degeneration, using a combination of molecular biology, animal models, and retinal organoid systems to better understand disease mechanisms. His laboratory also investigates gene therapy approaches, particularly adeno-associated virus (AAV)–mediated gene delivery and gene editing strategies, to restore retinal function in hereditary retinopathies. Through these efforts, his research aims to advance translational therapies for patients affected by genetic retinal diseases.